• English
  • 中文 (中国)
  • 日本語
  • Deutsch
  • 한국어
  • Français
  • Español
  • English
  • 中文 (中国)
  • 日本語
  • Deutsch
  • 한국어
  • Français
  • Español

Entos Pharmaceuticals Awarded funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine

Entos Pharmaceuticals Lab in Edmonton Alberta Canada

Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its breakthrough proprietary Fusogenix drug delivery platform, is pleased to announce it is receiving advisory services and funding of up to $5M from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) as part of the Government of Canada’s continuing support for the development of domestic COVID-19 vaccine candidates.

Thank you for your submission!

Contact Us








Subscribe to our newsletter! 

Questions? Get in touch
info@edmontonglobal.ca : 1-800-264-4952
Suite 100 - 10020 100 St.NW -T5J 0N5 Edmonton, AB
© Edmonton Global. All rights reserved